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A 31-year-old black man, previously resident in 
Angola, was referred to our hospital complaining 
of 6 months of progressively worsening shortness of 
breath with exertion and mucous productive cough. 
During this period, he had a significant weight loss 
(about 10 kg) and fatigue. His past medical history 
included suspected pulmonary tuberculosis (TB), 
for which he had completed 6 months of anti-
bacillary treatment in the year before. He is a 
construction worker and a nonsmoker, with no other 
environmental exposure or medication. The physical 
examination was remarkable for slight tachycardia 
(heart rate 105 beats·min−1), tachypnoea (respiratory 
rate 20 cycles·min−1), oxygen saturation of 94% and 
bilateral inspiratory crackles on both lungs. Figure 1 
shows the chest radiograph.
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Task 1




c) Micronodular diffuse opacities
d) Bilateral hilar node enlargement
e) Bilateral hilar node enlargement and 
micronodular diffuse opacities
Task 2
Considering the previous information, which 
diagnosis is less probable?
a) Miliary TB
b) Pulmonary metastasis of malignancy
c) Sarcoidosis
d) Langerhans cell histiocytosis
e) Silicosis
Figure 1 Posteroanterior chest radiograph.
e78 Breathe | June 2019 | Volume 15 | No 2
A disease with many faces
The patient underwent further investigation. 
First, laboratory testing showed mild leukopenia 
(4.2×109 cells·L−1; normal range (NR) 4.5–
11.0×109 cells·L−1), with normal differential 
white cell count, haemoglobin and platelets. 
He had a slightly abnormal liver profile: alkaline 
phosphatase 162 U·L−1 (NR 40–150 U·L−1), 
gamma glutamyltranspeptidase 109 U·L−1 (NR 
12–64 U·L−1), aspartate aminotransferase 56 U·L−1 
(NR 5–34 U·L−1) and alanine aminotransferase 
71 U·L−1 (NR 0–55 U·L−1). No renal disfunction or 
electrolyte imbalance was found. Sedimentation 
rate was elevated (66 mm·h−1; NR <11 mm·h−1), 
as was C-reactive protein (10.7 mg·L−1; NR 
<5 mg·L−1). Serological tests for infectious disease 
were negative (HIV, hepatitis B virus, hepatitis C 
virus, cytomegalovirus and Epstein–Barr virus). The 
level of serum angiotensin-converting enzyme (ACE) 
was raised (307 U·L−1; NR 16–85 U·L−1) with normal 
serum and 24-h urine calcium.
Secondly, three sputum specimens submitted for 
microscopic detection of acid-fast bacilli and PCR 
for Mycobacterium tuberculosis DNA were negative. 
Culture results for mycobacteria in sputum and 
blood were not yet available.
Thirdly, computed tomography (CT) of the chest 
was performed, which is presented in figure 2.
Answer 1
c) Micronodular diffuse opacities
Task 3
What would be your next approach?
a) No further investigation is needed: the high 
level of ACE is specific for sarcoidosis and CT 
findings are typical
b) Start empirical anti-bacillary treatment, 
since the most likely hypothesis is TB 
reactivation
c) Screening for blood tumour markers
d) Endobronchial ultrasound (EBUS)
e) Bronchofibroscopy with bronchoalveolar 
lavage (BAL) and biopsies
Answer 2
d) Langerhans cell histiocytosis
a) c)
b)
Figure 2 Chest CT shows a) multiple and bilateral micronodules with random distribution, traction bronchiectasis espe-
cially in upper lobes; and b) pleural thickening. c) View of coronal section.
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The serum ACE is not specific for sarcoidosis 
and could be high in a wide variety of conditions, 
including TB and silicosis. In CT scans, the most 
common parenchymal pattern in pulmonary 
sarcoidosis is micronodular lesions with 
perilymphatic distribution. A miliary micronodular 
distribution may warrant the inclusion of TB, 
pneumoconiosis and metastatic lesions in the 
differential diagnosis. Blood tumour markers are 
not indicated to diagnose malignancy, since they 
have low sensitivity and specificity. Our investigation 
for an occult cancer included abdominal CT 
scanning, which showed hepatosplenomegaly 
with millimetric hypodense nodules. There was 
no lymphadenopathy. No masses or nodules 
were reported in the gastrointestinal tract. Neck 
ultrasonography was normal. Additionally, serum 
electrophoresis had an increased gamma peak, the 
level of immunoglobulin G was high (25.9 g·L−1; NR 
7–16 g·L−1), but there was no monoclonal peak in 
serum immunofixation. In this specific case, EBUS 
is not a useful diagnostic exam due to absence of 
mediastinal lymphadenopathy.
We then performed a bronchofibroscopy, which 
is presented in figure 3. Microbiological tests 
were negative. Bronchial and transbronchial lung 
biopsies had no granulomas or neoplastic tissue. 
BAL showed lymphocytosis (25%) with slightly high 
CD4+/CD8+ and CD4+CD103+/CD4+ ratios (2.54 and 
0.25, respectively).
At this point, the results of cultures for 
mycobacteria of sputum, blood and BAL were 
negative. Lung function tests revealed a severe 
restrictive pattern: forced vital capacity (FVC) 1.28 L 
(24% predicted), forced expiratory volume in 1 s 
(FEV1) 1.09 L (25% pred), total lung capacity 2.28 L 
(39% pred) and decreased diffusing capacity of 
the lung for carbon monoxide (DLCO) at 19% pred, 
which rose to 70% pred when corrected for alveolar 
volume (transfer coefficient of the lung for carbon 
monoxide (KCO)).
After discussion in our multidisciplinary team, 
we proceeded to a CT-guided transthoracic biopsy of 
the right pleural thickening, which was insufficient 
for diagnosis. The procedure was complicated by 
symptomatic pneumothorax of moderate volume, 
prompting chest drainage and hospital admission. 
After 1 week without resolution, he was submitted 
to video-assisted thoracoscopic surgery (VATS). 
The lung presented with increased thickness, 
little elasticity and scattered micronodules. The 
parietal pleura also has dispersed micronodules. 
Wedge resection of the middle lobe and parietal 
pleura biopsy was performed, followed by chemical 
pleurodesis, without complications. Figure 4 shows 
the histopathological findings.
The patient was diagnosed with systemic 
sarcoidosis with involvement of lung, pleura, liver 
and spleen. During the diagnostic process, he 
became more breathless and developed moderate 
hypoxaemic respiratory failure with arterial oxygen 
tension 64 mmHg in room air (NR 80–100 mmHg). 
Additionally, a transthoracic echocardiogram 
revealed mild dyssynergy of the interventricular 
septum without other abnormalities. Cardiac 
magnetic resonance imaging excluded cardiac 
sarcoidosis.
Answer 3
e) Bronchofibroscopy with BAL and biopsies
Figure 3 Bronchofibroscopy, showing no endobronchial 
abnormalities.
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Task 4
How would you proceed?
a) Observation alone and repeat lung function 
test and chest CT scan in about 3 months
b) Start corticosteroids as they are the 
mainstay of treatment
c) Immunosuppression with methotrexate is 
the first choice of treatment
d) Urgent referral to lung transplant
e) As the patient has no eye symptoms, 





Figure 4 Microscopic examination of lung and pleu-
ral biopsies with haematoxylin and eosin stain. a) Non-
necrotising epithelioid granulomas with multinucleated 
giant cells (40× magnification) in b) interstitial and sub-
pleural location (10× magnification). c) Fibrotic areas and 
diffuse inflammatory lymphoplasmacytic infiltrate with 
granulomas in parietal pleura (10× magnification). No neo-
plastic tissue. Special stains for fungus and mycobacteria 
were negative (not shown).
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The patient started prednisolone 60 mg 
(1 mg·kg−1·day−1) for 10 days, gradually tapered 
to a maintenance dose of 20 mg. After 6 months 
of treatment, he experienced a progressive 
improvement of shortness of breath and fatigue. 
No other new symptoms were referred and ocular 
involvement was excluded. Lung function tests 
showed an increase of lung volumes (FVC 1.98 L 
(41% pred), FEV1 1.67 L (42% pred)) and of gas 
transfer (DLCO 33% pred, KCO 89% pred). The 
arterial oxygen tension was normal and the chest 
radiograph (figure 5) also showed an improvement 
of nodular opacities.
Currently, prednisolone has been reduced to 
10 mg and the patient will repeat chest CT scanning 
and lung function tests during the ninth month of 
treatment.
Answer 4
b) Start corticosteroids as they are the 
mainstay of treatment
Task 5
For the management of this patient, which of 
the following is not true?
a) It is useful to give supplementation 
with vitamin D and calcium to prevent 
osteopenia and osteoporosis
b) He was responsive to monotherapy with 
oral corticosteroids in moderate to high 
doses
c) If disease progresses with the current dose 
of prednisolone, addition of a second-line 
agent should be considered
d) Methotrexate is one immunosuppressant 
that can used as a corticosteroid-sparing 
agent
e) The goal of treatment involves regression of 
disease to give stabilisation and prevention 
of progression
Figure 5 Posteroanterior chest radiograph, showing mild 
bilateral nodular opacities.
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For primary prevention of glucocorticoid-induced 
osteoporosis, bisphosphonate should be used as 
the first treatment strategy in those patients who 
are expected to use glucocorticoid for an extended 
period of time. In the presence of osteopenia or 
osteoporosis, the supplementation with vitamin D 
and calcium can be considered with caution due 
to the risk of hypercalcaemia and hypercalciuria in 
patients with sarcoidosis.
Discussion
Sarcoidosis is a multisystemic disorder characterised 
by the presence of noncaseating granulomas in 
tissues. It most frequently affects the lungs but 
any organ may be involved.
Multiple environmental and microbial agents have 
been suggested to cause sarcoidosis and mycobacterial 
infection has always been one of the most important 
suspects. However, there is no consensus on microbial 
pathogenesis of sarcoidosis [1]. This disease occurs 
worldwide, affecting individuals of all ages and races, 
but northern Europeans and African Americans are 
the two ethnic groups consistently reported to be 
most affected [2]. Notably, in TB-endemic countries, 
sarcoidosis is frequently undiagnosed [3]. The 
incidence peaks in men aged 30–50 years and in 
women aged 50–60 years [4].
A combination of clinical, radiological 
and histological criteria is used to diagnose 
sarcoidosis. In the appropriate clinical context, 
observation of typical imaging features (bilateral 
hilar lymphadenopathy, perilymphatic nodules, 
interlobular septal thickening and bilateral perihilar 
opacities, predominant in the upper and middle 
lung fields) suggests the diagnosis of pulmonary 
sarcoidosis with high confidence. In contrast, 
miliary opacities are atypical and rare, present in 
<1% of cases of sarcoidosis [5]. Pleural disease is 
also sporadic in sarcoidosis, occurring in only 1–4% 
of patients, comprising pleural effusion, pleural 
thickening, pneumothorax and (rarely) pleural 
calcification [6].
Some clinical considerations could be useful in 
the presence of a miliary opacities pattern. History of 
exposure to beryllium and silica may be suggestive 
of pneumoconiosis. Cytological examination of BAL 
may detect possible malignancies and cultural 
examination can lead to a TB or fungal infection 
diagnosis. Nevertheless, diagnosis of sarcoidosis 
can be challenging, as in our case, due to remarkable 
clinical and imaging similarities of these illness. The 
diagnostic confirmation includes the presence of 
noncaseating granulomas in a biopsy specimen, 
if other causes for granulomatous inflammation 
are ruled out. The yield of diagnosis is higher if we 
combine endobronchial and transbronchial biopsies 
and EBUS-guided transbronchial needle aspiration. 
The BAL can also be an adjuvant measure, with 
lymphocytic predominance and elevated CD4+/
CD8+ ratio predictive of sarcoidosis. A positron 
emission tomography scan can also be used to 
assess the extent of disease and to uncover a 
suitable location for biopsy. In our case, because 
the patient had a pneumothorax with air leak, a 
more invasive approach was performed. The VATS 
was performed with both therapeutic and diagnostic 
purposes.
The management of sarcoidosis is variable and 
should take into account several factors, such 
as symptoms, organ involved and severity of the 
disease. For those who require treatment, the aim is 
to suppress and limit the burden of granulomatous 
inflammation. Accordingly, corticosteroids are the 
mainstay of therapy [7], while immunomodulatory 
and cytotoxic drugs are generally used in 
patients who fail to respond to or cannot tolerate 
corticosteroids, or who require unacceptably high 
doses of corticosteroids in the long term [8]. The 
optimal tools and timing to assess response to 
treatment in patients with pulmonary sarcoidosis 
have not yet been defined. According to expert 
opinion, a favourable response to treatment is 
generally defined by a symptomatic improvement, a 
reduction or clearing of radiographic abnormalities, 
and physiological improvement (increase in FVC 
≥10% or in DLCO ≥15% from baseline values) [9]. 
Lung transplantation might represent a treatment 
option for selected patients with end-stage disease, 
although the optimal timing for referral remains 
uncertain. For primary prevention of glucocorticoid-
induced osteoporosis, bisphosphonate should be 
used as the first treatment strategy [10].
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Answer 5
a) It is useful to give supplementation 
with vitamin D and calcium to prevent 
osteopenia and osteoporosis
Breathe | June 2019 | Volume 15 | No 2 e83
A disease with many faces
Conflict of interest
None declared.         
References
 1. Chen ES, Moller DR. Etiologies of sarcoidosis. Clin Rev Allergy 
Immunol 2015; 49: 6–18.
 2. Rybicki BA, Maliarik MJ, Major M, et al. Epidemiology, 
demographics, and genetics of sarcoidosis. Semin Respir Infect 
1998; 13: 166–173.
 3. Babu K. Sarcoidosis in tuberculosis-endemic regions: India. 
J Ophthalmic Inflamm Infect 2013; 3: 53.
 4. Spagnolo P. Sarcoidosis: a critical review of history and 
milestones. Clin Rev Allergy Immunol 2015; 49: 1–5.
 5. Criado E, Sanchez M, Ramirez J, et al. Pulmonary sarcoidosis: 
typical and atypical manifestations at high-resolution 
CT with pathologic correlation. Radiographics 2010; 30: 
1567–1586.
 6. Soskel NT, Sharma OP. Pleural involvement in sarcoidosis: case 
presentation and detailed review of the literature. Semin Respir 
Crit Care Med 1992; 13: 492–514.
 7. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for 
pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; 2: 
CD001114.
 8. Baughman RP, Grutters JC. New treatment strategies for 
pulmonary sarcoidosis: antimetabolites, biological drugs, 
and other treatment approaches. Lancet Respir Med 2015; 3: 
813–822.
 9. Spagnolo P, Rossi G, Trisolini R, et al. Pulmonary sarcoidosis. 
Lancet Respir Med 2018; 6: 389–402.
 10. Burke RR, Rybicki BA, Rao DS. Calcium and vitamin 
D in sarcoidosis: how to assess and manage. Semin Respir Crit 
Care Med 2010; 31: 474–484.
